)
Edge26 Jun 2026
The Universal Language: Inventing the Barcode
How lines in the sand on a Miami beach became the most scanned symbol in human history, and why it took decades for anyone to care.
Matinas BioPharma
Matinas BioPharma (MTNB) investor relations material
Matinas BioPharma Registration filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Registration filing summary16 Jun, 2026
Company overview and business model
Clinical-stage biopharmaceutical company leveraging lipid nanocrystal (LNC) platform for drug delivery.
Lead candidate MAT2203 (oral amphotericin B) targets invasive fungal infections, with Phase 3 trial planned pending partnership or capital raise.
Internal pipeline development paused after an 80% workforce reduction in late 2024; focus shifted to strategic alternatives and partnerships.
Maintains active FDA IND for MAT2203 and ongoing intellectual property prosecution.
Financial performance and metrics
As of June 15, 2026, public float market value was $5,579,577, with 6,398,597 shares held by non-affiliates at $0.872 per share.
No securities sold under General Instruction I.B.6 of Form S-3 in the prior 12 months.
Auditors included a going concern explanatory paragraph in the latest financial statements.
Use of proceeds and capital allocation
Net proceeds from securities sales intended for working capital and general corporate purposes.
Specific use of proceeds for each offering to be detailed in the relevant prospectus supplement.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Matinas BioPharma
- Q1 2026 net loss widened to $1.92M, cash fell to $2.4M, and delisting risk persists.MTNB
Q1 20268 May 2026 - Net loss fell to $10.3M in 2025, but cash runway is short without new funding or a MAT2203 deal.MTNBQ4 202531 Mar 2026
- Oral MAT2203 could transform antifungal therapy by offering safer, more flexible treatment.MTNBFireside Chat3 Feb 2026
- MAT2203 licensing advances, net loss narrows, but cash shortfall raises going concern doubts.MTNBQ2 20241 Feb 2026
- Registering 16.9M shares for resale post-private placement, with ongoing strategic and financial risks.MTNBRegistration Filing16 Dec 2025
- Proxy seeks approval for director elections, compensation, reverse split, share increase, and new equity plan.MTNBProxy Filing2 Dec 2025
- Proxy seeks approval for director elections, compensation, reverse split, share increase, and new equity plan.MTNBProxy Filing2 Dec 2025
- Approval sought for major stock issuance, auditor ratification, and potential meeting adjournment.MTNBProxy Filing2 Dec 2025
- Vote on major stock issuance, auditor ratification, and board changes at April 2025 virtual meeting.MTNBProxy Filing2 Dec 2025
Next Matinas BioPharma earnings date
Q2 20265 Aug, 2026
Matinas BioPharma
Next Matinas BioPharma earnings date
Q2 20265 Aug, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage